Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424156 | 0.79 | SCN4A (0.41) | RAPGEF4MAPTKDM4ELMNAKMT2A | |
| SCHEMBL3437814 | 0.79 | RAPGEF4 (0.35) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL4342022 | 0.77 | ALDH1A1 (0.46) | ACHEALDH1A1GAAKMT2ACYP1A2 | |
| SCHEMBL11420240 | 0.73 | RAPGEF4 (0.43) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL242786 | 0.73 | RAPGEF4 (0.43) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL4520516 | 0.72 | — | — | |
| Phosphine SCHEMBL22634061 | 0.71 | RAPGEF4 (0.41) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL129762 | 0.71 | ACHE (0.57) | RAPGEF4ACHEALDH1A1MAPTLMNA | |
| SCHEMBL10798387 | 0.71 | RAPGEF4 (0.41) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL2122566 | 0.70 | KMT2A (0.31) | ACHEALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9362122-B2 | Process for contact doping | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-06-07 | — | — | US | claimed |
| WO-2012137211-A1 | PROCESS FOR CONTACT DOPING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2012-10-11 | — | — | WO | claimed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | claimed |
| US-12565508-B2 | Group III and lanthanide bis-phenyl-phenoxy metal-ligand complexes | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12497414-B2 | Group III and Lanthanide bis-phenyl-phenoxy metal-ligand complexes | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4606806-A1 | TRANSITION METAL COMPOUND AND CATALYST COMPOSITION COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2025-08-27 | — | — | EP | disclosed |
| EP-4097151-B1 | GROUP III AND LANTHANIDE BIS-PHENYL-PHENOXY METAL-LIGAND COMPLEXES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3990503-B1 | OLEFIN POLYMERIZATION CATALYSTS BEARING A THIAZOLE OR IMIDAZOLE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12286502-B2 | Olefin polymerization catalysts bearing a thiazole or imidazole | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-04-29 | — | — | US | disclosed |
| EP-4298135-B1 | BIS-PHENOXY-ETHER LIGANDS FOR GROUP IV POLYOLEFIN CATALYSIS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-01-02 | — | — | US | disclosed |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | KONRADI ANDREI W (US) | 2003-07-24 | — | — | US | disclosed |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-03 | — | — | US | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0199260-B1 | BORONIC ACID ADDUCTS OF TECHNETIUM-99M DIOXIME COMPLEXES | E.R. Squibb & Sons, Inc. (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4705849-A | Boronic acid adducts of technetium-99m dioxime complexes | E. R. SQUIBB & SONS, INC. (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0199260-A2 | Boronic acid adducts of technetium-99M dioxime complexes | E.R. Squibb & Sons, Inc. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | VCAM1, ICAM1, ITGB4 | RAPGEF4 1132/4885ACHE 747/4885ALDH1A1 386/4885 |
| US-12565508-B2 | Group III and lanthanide bis-phenyl-phenoxy metal-ligand complexes | SCO2, CBR3, SOD1 | RAPGEF4 3046/4885ACHE 3347/4885ALDH1A1 4089/4885 |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | RAPGEF4 927/4885ACHE 814/4885ALDH1A1 1759/4885 |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | RAPGEF4 1462/4885ACHE 652/4885ALDH1A1 260/4885 |
| US-12497414-B2 | Group III and Lanthanide bis-phenyl-phenoxy metal-ligand complexes | SSB, SOD1, LGALS3 | RAPGEF4 1324/4885ACHE 1607/4885ALDH1A1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.